GroopmanJ.E., ItriL.M.: Chemotherapy-induced anemia in adults: incidence and treatment.J Natl Cancer Inst1999; 91: 1616–1634.
2.
CellaD.: The functional assessment of Cancer Therapy-Anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue.Semin Hematol1997; 34(suppl 2): 13–19.
3.
PortenoyR.K., ItriL.M.: Cancer-related fatigue: guidelines for evaluation and management.The Oncologist1999; 4: 1–10.
4.
AshburyF.D., FinlayH., ReynoldsB.: A Canadian survey of cancer patients experiences: are their needs being met?J pain Symptom Manage1998, 16: 298–306.
5.
WooB., DibbleS.L., PiperB.F.: Differences in fatigue by treatment methods in women with breast cancer.Oncol Nurs Forum1998, 25: 915–920.
6.
CellaD., PetermanA., PassikS.: Progress toward guidelines for the management of fatigue.Oncology1998; 12: 369–377.
KumarP.: Tumor hypoxia and anemia: impact upon the efficacy of radiation therapy. Program and abstracts of the Anemia Y2K Symposium, December 3 1999, New Orleans (USA). 9. Soignet S: Treatment of cancer-related anemia: erythropoietin and quality of life.Semin Hematol 37 (2000);4(suppl 6): 9–13.
9.
DemetriG., KrisM., WadeJ.: Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study: Procrit Study Group.J Clin Oncol1998; 16: 3412–3425.
10.
CheungW., MintonN., GunawardenaK.: The pharmacokinetics and pharmacodynamics of epoetin alfa once weekly vs epoetin alfa three times weekly.Blood2000, 96: A1270.
11.
GabriloveJ.L., EinhornL.H., LivingstonR.B.: Once-weekly dosing of epoetin alfa is similar to three-times-weekly dosing in increasing hemoglobin and quality of life.J Clin Oncol2001.
12.
HarrisonL.B., ShashaD., WhiteC., RamdeenB.: Radiotherapy-associated anemia: the scope of the problem.Oncologist 2000; 5 Suppl2: 1–7.
